ANZCTR search results

The purpose of this study is to determine whether a new treatment, called Targeted Osmotic Lysis (TOL), is a safe and tolerable treatment for patients with well-differentiated cutaneous squamous cell carcinoma, a specific type of skin cancer. Who is it for? You may be eligible for this study if you are an adult between the ages of 40-75 who has been diagnosed with well-differentiated cutaneous squamous cell carcinoma on the head, neck, mid-upper anterior chest or arms. Study details All participants in this study will be asked to take digoxin, a well established medication, and attend sessions every 6 days for 3 weeks to receive TOL treatment. TOL treatment will include laying in the CPEFG unit for 2 hours each treatment, while also taking a daily dose of digoxin orally during the active treatment period. During each session, participants will be monitored via ECG and using photographs, as well as for any side effects that may occur. Participants will also be followed up for 30 days after the final session for any additional side effects, to monitor their cancer and complete questionnaires. It is hoped that this research will help determine if TOL is a safe and effective treatment option for those who have been diagnosed with diagnosed with well-differentiated cutaneous squamous cell carcinoma.

This study is testing a nasal spray called SDS089 in adults who have been newly diagnosed with pulmonary arterial hypertension (PAH), a condition that affects blood flow in the lungs. Participants will receive a single dose of the nasal spray during a routine heart catheterisation procedure, allowing researchers to measure how it affects blood pressure and circulation in the lungs before and after treatment. The study also aims to assess the safety and tolerability of the treatment. The study hypothesises that a single dose of SDS089 will reduce resistance in the lung blood vessels, improving blood flow shortly after administration.

Brief description of the study purpose This study aims to better understand how the immune system responds in people with acute pancreatitis (AP), including severe cases that can cause life-threatening organ failure. By comparing patients with pancreatitis to different control groups, researchers hope to identify immune changes that could guide future treatments. Who is it for? You may be eligible if you are a male or female (18 years or older) admitted to hospital with acute pancreatitis, including severe cases requiring intensive care, with pancreatic cancer undergoing surgery, critically ill patients without pancreatic disease, patients with other abdominal conditions, and healthy volunteers. Study details Participants with acute pancreatitis will provide blood samples on several days during their hospital stay (up to Day 28) to assess immune responses over time. Some patients undergoing surgery (for pancreatitis or cancer) may also provide pancreatic tissue samples already being removed as part of their standard treatment. Control group participants will provide blood and/or tissue samples depending on their health condition. All participants will receive standard medical care, and there is no randomisation. Blood and tissue tests will be performed to measure immune markers, cytokines, and other laboratory parameters. It is hoped that this research will improve understanding of how the immune system responds in pancreatitis and related conditions, ultimately guiding new strategies for diagnosis and treatment to improve patient outcomes.

Mobile phones are ubiquitous in healthcare settings as patients, visitors and healthcare workers use them frequently for work-related and personal purposes. Mobile phones act as significant fomites in healthcare settings, especially in ICU, and may potentially be putting patients at risk of contracting hospital acquired infections. Therefore, solutions specifically tailored to healthcare settings are required for the sanitisation of mobile phones. Despite evidence in favour of UV-C devices for this purpose, there remains a paucity of evidence supporting their effectiveness in real-world clinical environments such as the ICU. Therefore, the purpose of this study is to investigate their contamination pre and post UV-C sanitisation.

This study is being conducted to assess the safety of a novel health supplement (PMB676) in healthy volunteers. The supplement is an extract of green-lipped mussels containing an ingredient called plasmalogens, which are a type of lipid naturally present in the cells of our bodies. Preliminary research has shown potential for a plasmalogen supplement to support cognitive decline in aging. The present study will not be investigating the effectiveness of the supplement but aims to investigate if it is safe to take and if changes in the lipid levels within the blood and blood cells can be seen after taking the supplement for 12 weeks.

Mobile phones are ubiquitous in healthcare settings as patients, visitors and healthcare workers use them frequently. Mobile phones act as significant fomites in healthcare settings, especially in ICU, and may potentially be putting patients at risk of contracting healthcare-associated infections. Therefore, mobile phone sanitisation solutions are required for healthcare settings, and Ultraviolet-C (UV-C) devices offer a promising solution to this problem. However, it is yet to be investigated whether healthcare workers will be willing to use UV-C devices frequently to disinfect their phones at work. Hence, this study aims to investigate the perceptions of healthcare workers regarding mobile phone contamination, and their beliefs regarding the viability and utility of UV-C mobile phone sanitisation in the intensive care unit.

This study will test whether GameGear Nodal Impact Attenuation soft padded headgear can reduce the risk and severity of concussion in collision-sport athletes. Players from participating teams in Victoria, Queensland and the ACT will take part in a randomised crossover trial, in which they will wear the headgear during some matches and not wear it during others. We will compare concussion rates and concussion severity between these two conditions. If a participating player sustains a suspected concussion during a match, they will undergo specialist clinical review and provide a blood sample to measure biomarkers of brain injury. A smaller subgroup of players will also wear instrumented mouthguards during selected matches to measure head impacts, and will provide additional blood samples after non-injury matches to help assess the biological effects of head impacts when playing with and without headgear. The study aims to improve understanding of whether this headgear provides meaningful protection in real-world sport and to help guide safer sporting practices.

This project aims to support the mental health of children aged 7–12 by helping them manage perfectionism. High perfectionism in childhood is linked to anxiety, depression, eating issues, and school-related stress. Teaching children healthier thinking habits early can improve their wellbeing now and protect their mental health in the future. Growing Strong Minds is a program designed to reduce perfectionism in children. It is delivered in a new way: instead of being run by teachers or clinicians, parents learn how to guide their children through the program at home. This approach increases access to support and helps parents model positive behaviours in everyday life. Our pilot study, supported by a Channel 7 grant, showed promising early results. In this project, we will refine the program based on our pilot findings and test the updated version in a larger study. Families will be randomly assigned either to the intervention or to a control group, where parents receive general information about perfectionism. All families will complete online surveys. Parents in the intervention group will join five online guidance sessions, and both parents and children will complete home activities to practise new skills. We expect that children who take part in Growing Strong Minds will show better mental health and academic outcomes compared with the control group, and that the updated program will have higher completion rates than our pilot.

Prospective parallel randomised controlled feasibility trial. The study aims to adapt the existing evidence-based Take Charge intervention (in partnership with people with lived experience of stroke) to tailor it to the needs of younger adults (18 to 55 years) with chronic stroke (> 6 months post-stroke), and to investigate the feasibility of delivering it via telehealth in a randomised pilot study. We hypothesize that it will be feasible to deliver the adapted Take Charge intervention to younger adults with chronic stroke via telehealth, with at least 85% of randomised participants completing the trial at 3 months post-randomisation.

Shoulder pain is the third most common musculoskeletal complaint managed by general practitioners (GPs) in Australia, with rotator cuff–related shoulder pain (RCRSP) being the most frequent presentation. Despite clinical practice guidelines recommending education and exercise for the management of RCRSP, these approaches are poorly implemented in routine care. This problem is further exacerbated in rural and remote communities, where access to care is limited. There is therefore a need to develop convenient, low-cost, and accessible strategies to support people with RCRSP. The INTEL trial aims to determine the effectiveness of adding internet-delivered care, with or without telehealth, to usual care for reducing pain and disability at 12 months post-randomisation in people with RCRSP. The trial will also compare the cost effectiveness of each treatment from a healthcare perspective and societal perspective (including absenteeism) over 12 months.